ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerRowan Miller, Lucy Yates, Christopher J. Lord et al.|Annals of Oncology|2020Cited by 478
The Tumor Microenvironment of Clear-Cell Ovarian CancerMichael-John Devlin, Frances R. Balkwill, Rowan Miller et al.|Cancer Immunology Research|2022Cited by 41